Cartesian Therapeutics, Inc.
RNAC
Rank in Stocks
#18381
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Share Price
$6.09
Market Cap
$184.26M
Change (1 day)
-2.87%
Change (1 year)
812.63%
Country
US
Trade Cartesian Therapeutics, Inc. (RNAC)
Category
Healthcare
Earnings for Cartesian Therapeutics, Inc. (RNAC)
Earnings in 2026 TTM: 0
According to Cartesian Therapeutics, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Cartesian Therapeutics, Inc. from 2026 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
